We are live on ! Find out more
WP

Woodline Partners Portfolio holdings

AUM $26.4B
1-Year Est. Return 44.85%
This Fund
S&P 500
This Quarter Est. Return
+21.26%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$3.77B
AUM Growth
+$720M
Cap. Flow
+$280M
Cap. Flow %
7.43%
Top 10 Hldgs %
22.38%
Holding
294
New
116
Increased
45
Reduced
52
Closed
77

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$115M
2
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$93.9M
3
NXPI icon
NXP Semiconductors
NXPI
+$57.1M
4
LLY icon
Eli Lilly
LLY
+$51.1M
5
QRVO icon
Qorvo
QRVO
+$47.7M

Top Sells

Rank Stock Value
1
MCHP icon
Microchip Technology
MCHP
+$72.6M
2
BMY icon
Bristol-Myers Squibb
BMY
+$66.5M
3
AMZN icon
Amazon
AMZN
+$65.6M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$58.8M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$53.4M

Sector Composition

Rank Sector Weight
1 Healthcare 42.9%
2 Technology 32.83%
3 Communication Services 8.98%
4 Financials 3.92%
5 Consumer Discretionary 3.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRIL
101
DELISTED
Trillium Therapeutics Inc.
TRIL
$11.2M 0.3%
761,465
-69,032
-8% -$995K
CANO
102
DELISTED
Cano Health, Inc.
CANO
$11.1M 0.29%
+8,288
New +$9.48M
INCY icon
103
Incyte
INCY
$24.3B
$11M 0.29%
+126,508
New +$10.9M
KNTE
104
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$11M 0.29%
+276,451
New +$11.1M
SMPL icon
105
Simply Good Foods
SMPL
$1.01B
$10.9M 0.29%
+348,110
New +$8.1M
LULU icon
106
lululemon athletica
LULU
$13.9B
$10.8M 0.29%
+31,162
New +$10.8M
ARVN icon
107
Arvinas
ARVN
$590M
$10.6M 0.28%
+125,213
New +$4.32M
ERIC icon
108
Ericsson
ERIC
$33.7B
$10.6M 0.28%
889,274
+423,171
+91% +$4.96M
HZNP
109
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$10.6M 0.28%
144,661
-790,942
-85% -$58.8M
MAACU
110
DELISTED
Montes Archimedes Acquisition Corp. Unit
MAACU
$10.6M 0.28%
+1,006,452
New +$10.2M
CDW icon
111
CDW
CDW
$19.3B
$10.5M 0.28%
+79,864
New +$10.5M
KYMR icon
112
Kymera Therapeutics
KYMR
$8.58B
$10.5M 0.28%
169,687
+3,470
+2% +$169K
ITCI
113
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$10.3M 0.27%
+324,767
New +$8.54M
DYN icon
114
Dyne Therapeutics
DYN
$4.83B
$10.3M 0.27%
490,986
+224,187
+84% +$4.43M
VIE
115
DELISTED
Viela Bio, Inc. Common Stock
VIE
$10.2M 0.27%
+284,927
New +$9.98M
SPRY icon
116
ARS Pharmaceuticals
SPRY
$525M
$9.99M 0.26%
+215,536
New +$7.2M
REGN icon
117
Regeneron Pharmaceuticals
REGN
$78.1B
$9.76M 0.26%
+20,204
New +$10.9M
WST icon
118
West Pharmaceutical
WST
$24.4B
$9.63M 0.26%
+33,980
New +$9.54M
XRAY icon
119
Dentsply Sirona
XRAY
$2.85B
$9.56M 0.25%
182,570
-115,409
-39% -$5.69M
SWTX
120
DELISTED
SpringWorks Therapeutics
SWTX
$9.41M 0.25%
129,832
-92,544
-42% -$5.96M
RETA
121
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$9.04M 0.24%
+73,097
New +$9.61M
LUNG icon
122
Pulmonx
LUNG
$86.2M
$8.83M 0.23%
+127,976
New +$6.27M
SNRHU
123
DELISTED
Senior Connect Acquisition Corp. I Unit
SNRHU
$8.75M 0.23%
+850,000
New +$8.76M
SGEN
124
DELISTED
Seagen Inc. Common Stock
SGEN
$8.72M 0.23%
49,797
-267,690
-84% -$49.9M
OPTU
125
Optimum Communications Inc
OPTU
$345M
$8.71M 0.23%
229,984
-820,011
-78% -$25.7M
3 4
5
6 7

Similar funds

PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
TCIIS
TIAA-CREF Individual & Institutional Services New York $26B AUM
WorldQuant Millennium Advisors
WorldQuant Millennium Advisors New York $25.9B AUM 22.07% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $27B AUM 24.49% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $25.6B AUM 30.22% 1-Year Est. Return
VAI
Vanguard Advisers Inc Malvern, Pennsylvania $25.5B AUM

Woodline Partners's Q4 2020 Portfolio in Review

As of Q4 2020, Woodline Partners held 294 positions worth $3.77B, up 24% from $3.05B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Woodline Partners deployed $280M of net new capital in Q4 2020, opening 116 new positions and adding to 45 existing holdings. Its largest new stake was Amgen: 500,520 shares worth $115M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 45% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $58.8M trimmed.

  • Woodline Partners's largest Q4 2020 buy was Amgen: 500,520 shares worth $115M.
  • Woodline Partners added most to Eli Lilly in Q4 2020, an estimated $51.1M increase.
  • Woodline Partners's biggest Q4 2020 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $58.8M.
  • Woodline Partners fully exited Microchip Technology in Q4 2020, selling an estimated $72.6M.
  • Woodline Partners's ten largest holdings make up 22% of its $3.77B portfolio in Q4 2020.
  • Woodline Partners opened 116 new positions and closed 77 in Q4 2020.
  • Woodline Partners's portfolio value rose 24% quarter-over-quarter to $3.77B.

Based on Woodline Partners's 13F filing for Q4 2020, filed 16 Feb 2021.